Analyst ratings, especially those initiating coverage with a positive outlook, tend to influence investor sentiment and can lead to short-term price increases. The Overweight rating and $6 price target set by Capital One for Heron Therapeutics suggest a strong vote of confidence in the company's future performance, likely leading to increased investor interest and a rise in stock price.